About Amicus Therapeutics, Inc.
https://amicusrx.comAmicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data.
CEO
Bradley L. Campbell
Compensation Summary
(Year 2023)
ETFs Holding This Stock
Summary
Showing Top 3 of 146
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
UBS
Buy
JP Morgan
Overweight
Morgan Stanley
Overweight
Wells Fargo
Overweight
Leerink Partners
Market Perform
Citigroup
Neutral
Grade Summary
Showing Top 6 of 9
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:29.53M
Value:$424.7M
WELLINGTON MANAGEMENT GROUP LLP
Shares:28.63M
Value:$411.68M
BLACKROCK, INC.
Shares:25.85M
Value:$371.71M
Summary
Showing Top 3 of 369
About Amicus Therapeutics, Inc.
https://amicusrx.comAmicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $169.06M ▲ | $113.45M ▼ | $17.31M ▲ | 10.24% ▲ | $0.06 ▲ | $47.86M ▲ |
| Q2-2025 | $154.69M ▲ | $148.94M ▲ | $-24.42M ▼ | -15.79% ▲ | $-0.08 ▼ | $-5.76M ▼ |
| Q1-2025 | $125.25M ▼ | $121.5M ▲ | $-21.69M ▼ | -17.31% ▼ | $-0.07 ▼ | $-4.75M ▼ |
| Q4-2024 | $149.71M ▲ | $118.9M ▲ | $14.74M ▲ | 9.85% ▲ | $0.05 ▲ | $21.93M ▲ |
| Q3-2024 | $141.52M | $106.58M | $-6.73M | -4.75% | $-0.02 | $21.65M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $263.84M ▲ | $868.81M ▲ | $638.39M ▲ | $230.42M ▲ |
| Q2-2025 | $231M ▼ | $815.3M ▲ | $611M ▲ | $204.3M ▲ |
| Q1-2025 | $250.57M ▲ | $789.84M ▲ | $596.28M ▲ | $193.56M ▼ |
| Q4-2024 | $249.95M ▲ | $785.03M ▼ | $590.99M ▼ | $194.04M ▲ |
| Q3-2024 | $249.76M | $786.56M | $607.73M | $178.82M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $17.31M ▲ | $35.66M ▲ | $-1.3M ▲ | $-1.32M ▼ | $31.85M ▲ | $35.28M ▲ |
| Q2-2025 | $-24.42M ▼ | $-26.53M ▼ | $-5.78M ▲ | $-400K ▲ | $-22.72M ▲ | $-28.93M ▼ |
| Q1-2025 | $-21.69M ▼ | $7.76M ▲ | $-32.86M ▼ | $-11.7M ▼ | $-31.98M ▼ | $7.55M ▲ |
| Q4-2024 | $14.74M ▲ | $-3.92M ▲ | $-20.39M ▼ | $1.1M ▼ | $-20.1M ▼ | $-4.2M ▲ |
| Q3-2024 | $-6.73M | $-22.97M | $34.27M | $18.19M | $24.46M | $-23.33M |
Revenue by Geography
| Region | Q4-2024 | Q3-2025 | Q2-2025 | Q1-2025 |
|---|---|---|---|---|
 NonUS | $120.00M ▲ | $80.00M ▼ | $80.00M ▲ | $60.00M ▼ |
 UNITED STATES | $80.00M ▲ | $60.00M ▼ | $50.00M ▼ | $40.00M ▼ |
CEO
Bradley L. Campbell
Compensation Summary
(Year 2023)
ETFs Holding This Stock
Summary
Showing Top 3 of 146
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
UBS
Buy
JP Morgan
Overweight
Morgan Stanley
Overweight
Wells Fargo
Overweight
Leerink Partners
Market Perform
Citigroup
Neutral
Grade Summary
Showing Top 6 of 9
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:29.53M
Value:$424.7M
WELLINGTON MANAGEMENT GROUP LLP
Shares:28.63M
Value:$411.68M
BLACKROCK, INC.
Shares:25.85M
Value:$371.71M
Summary
Showing Top 3 of 369